Abstract
Research Overview
Rising Prevalence of Cancer in Europe Creates Need for Advanced Diagnostics Enabling Early Detection
Immunohistochemistry (IHC) has emerged as an important tool for cancer diagnostics due to the growing appeal of new molecular diagnostic tests that can detect cancer in its earliest stages or even predict onefs predisposition to the disease. The success of recent campaigns in Europe in improving patient management by encouraging people to be screened for certain subtypes of cancer suggests that the primary focus of IHC diagnostic testing should be on early disease detection and treatment. Cancers of the breast, prostate as well as colon are particularly responsive to early detection and treatment, yielding significantly higher survival rates as a result. Timely detection also helps decrease the need for expensive therapies, invasive procedures and potentially harmful imaging techniques, which in turn, reduce bed occupancy rates as well as the overall burden on the healthcare system. These factors are together driving governments to implement national cancer screening programmes.
This Frost & Sullivan research service provides a comprehensive analysis of the European immunohistochemistry diagnostics market. It examines the business potential for this market in Europe, taking into account industry dynamics and drivers in each region. It also provides an overview of the marketfs attractiveness, which can be very helpful to companies interested in entering the market or increasing their presence.
Cancer Testing Becomes Easier with Improved Automated Diagnostic Techniques
The antibodies used to detect cancer today are increasingly specific and sensitive and the analysers available in the market are faster and easier to use than ever before. Due to advancements in automation, the technical performance of assays has improved substantially, which has helped reduced the total assay time as well as the overall costs of reagents. "Over the next three years, these technological improvements are expected to result in faster turnaround times, higher throughput and enhanced ease of use, which in turn, is likely to increase the demand for IHC tests," says the analyst of this research service.
Higher accuracy of tests can increase the levels of expertise and skills, allowing for technological innovations and leading to reduced complexities within research and development (R&D). Additionally, it can provide access to greater R&D capacity as well as to therapeutic expertise, thereby bringing about alignment with diagnostic tests for safer and more effective therapies.
View Cart
